Form 4 SUTRO BIOPHARMA, INC. For: Jan 29 Filed by: ALBINI EDWARD C
Sutro Biopharma, Inc. (STRO)
Last sutro biopharma, inc. earnings: 11/8 07:00 am
Check Earnings Report
Company Research
Source: SEC EDGAR
Impact Snapshot
Event Time:
STRO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
STRO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
STRO alerts
High impacting Sutro Biopharma, Inc. news events
Weekly update
A roundup of the hottest topics
STRO
News
- Sutro Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference GlobeNewswire
- Sutro Biopharma and Boehringer Ingelheim BioXcellence™ collaboration: Established first-in-class cell-free capabilities at commercial scaleGlobeNewswire
- Sutro Biopharma: I Don't Buy That Their Pipeline Is Worthless [Seeking Alpha]Seeking Alpha
- Sutro Biopharma, Inc. (NASDAQ: STRO) had its price target lowered by analysts at Wells Fargo & Company from $5.00 to $4.00. They now have an "equal weight" rating on the stock.MarketBeat
- Sutro Biopharma, Inc. (NASDAQ: STRO) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $17.00 price target on the stock.MarketBeat
STRO
Earnings
- 11/13/24 - Beat
STRO
Sec Filings
- 12/10/24 - Form 8-K
- 12/3/24 - Form 4
- STRO's page on the SEC website